Showing 561 - 580 results of 1,337 for search '"Fibrosis"', query time: 0.05s Refine Results
  1. 561

    Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B by S. N. Batskikh, E. V. Vinnitskaya, E. S. Sbikina, Zh. V. Borunova, A. S. Dorofeev, Yu. G. Sandler

    Published 2020-09-01
    “…In 85 patients, liver fibrosis was scored F0-F2 with METAVIR, 25 persons had severe fibrosis (F4 in 23, F3 in 2). …”
    Get full text
    Article
  2. 562

    The Possible Potential Therapeutic Targets for Drug Induced Gingival Overgrowth by Tamilselvan Subramani, Vidhya Rathnavelu, Noorjahan Banu Alitheen

    Published 2013-01-01
    “…Fibrosis is one of the largest groups of diseases for which there is no therapy but is believed to occur because of a persistent tissue repair program. …”
    Get full text
    Article
  3. 563
  4. 564
  5. 565

    Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition by Mary E. Peek, Abhinav Bhatnagar, Nael A. McCarty, Susu M. Zughaier

    Published 2012-01-01
    “…Pseudomonas aeruginosa is the most common pathogen that persists in the cystic fibrosis lungs. Bacteria such as P. aeruginosa secrete siderophores (iron-chelating molecules) and the host limits bacterial growth by producing neutrophil-gelatinase-associated lipocalin (NGAL) that specifically scavenges bacterial siderophores, therefore preventing bacteria from establishing infection. …”
    Get full text
    Article
  6. 566

    The impact of absorbable hemostatic agents on wound healing in an experimental penile fracture rat model by Mehmet Ezer, Engin Doğantekin, Muzaffer Çaydere, Aykut Koç, Çağrı Öktem, Sema Hücümenoğlu

    Published 2025-01-01
    “…Key parameters assessed included primary healing, fibrosis, inflammation, and cavernous tissue healing. …”
    Get full text
    Article
  7. 567

    The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study by Michael P. Curry, Edward Tam, Caitlin Schneider, Noha Abdelgelil, Tarek Hassanien, Nezam H. Afdhal

    Published 2024-01-01
    “…Current AASLD, AGA, and ADA guidelines recommend assessment for liver fibrosis in all patients with NAFLD. Serum biomarkers for fibrosis, while widely available, have notable limitations. …”
    Get full text
    Article
  8. 568

    The Dose-Dependent Effects of Spironolactone on TGF-β1 Expression and the Vulnerability to Atrial Fibrillation in Spontaneously Hypertensive Rats by Mirong Tang, Yan Chen, Fuqing Sun, Liangliang Yan

    Published 2021-01-01
    “…This study tends to assess the dose-dependent effects of spironolactone on TGF-β1 expression, atrial fibrosis, and the vulnerability to atrial fibrillation in spontaneously hypertensive rats (SHRs) and tries to clarify the association of atrial fibrosis with the vulnerability to atrial fibrillation. …”
    Get full text
    Article
  9. 569

    Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis by Andrea Gramegna, Giuseppe Cimino, Marco Cipolli, Giovanna Gandini, Maria Adelaide Calderazzo, Angelica Profiti, Federica Piedepalumbo, Francesco Blasi

    Published 2025-01-01
    “…Abstract This retrospective population-based study investigated the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on inhaled medication adherence in people with cystic fibrosis (pwCF). Prescription refill rate (PRR) for several inhaled medications were compared before and after ETI introduction in three major Italian CF centers. …”
    Get full text
    Article
  10. 570

    The Contribution of the Airway Epithelial Cell to Host Defense by Frauke Stanke

    Published 2015-01-01
    “…In the context of cystic fibrosis, the epithelial cell has been characterized in terms of its ion transport capabilities. …”
    Get full text
    Article
  11. 571

    The Role of PPAR Gamma in Systemic Sclerosis by Andréa Tavares Dantas, Michelly Cristiny Pereira, Moacyr Jesus Barreto de Melo Rego, Laurindo Ferreira da Rocha, Ivan da Rocha Pitta, Cláudia Diniz Lopes Marques, Angela Luzia Branco Pinto Duarte, Maira Galdino da Rocha Pitta

    Published 2015-01-01
    “…Fibrosis is recognized as an important feature of many chronic diseases, such as systemic sclerosis (SSc), an autoimmune disease of unknown etiology, characterized by immune dysregulation and vascular injury, followed by progressive fibrosis affecting the skin and multiple internal organs. …”
    Get full text
    Article
  12. 572
  13. 573

    Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage by Yong-fen Zhu, Jin Wang, Jia-zhui Fang, Qiao Yang, Fang-fang Lv

    Published 2020-01-01
    “…After fibrosis matching, in patients with F0–2 fibrosis, the rate of interface hepatitis over grade 2 in CHB was significantly higher than that in NAFLD (100% vs. 0%; P<0.0001). …”
    Get full text
    Article
  14. 574

    Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis by Changzhou Cai, Xin Song, Xueyang Chen, Weihua Zhou, Qi Jin, Shenghui Chen, Feng Ji

    Published 2021-01-01
    “…In patients with ALD/NAFLD, CAP was feasible for identifying and screening steatosis, and LSM was accurate for diagnosing fibrosis, especially severe fibrosis and cirrhosis.…”
    Get full text
    Article
  15. 575

    Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study by Hanan M. Fayed, Ali A. Ghweil, Mona M. AbdelMeguid

    Published 2019-01-01
    “…We aimed to investigate changes in the circulating monocyte phenotypes in response to Daclatasvir-Sofosbuvir (SOF/DCV) therapy in chronic hepatitis C (CHC) and relate findings to the viral kinetics and the fibrosis score. Methods. A longitudinal study involving 100 treatment-naïve patients and 30 healthy controls, tested for liver function, fibrosis scores (AST to platelet ratio index, FIB-4), and blood monocyte subsets based on CD14/CD16 expression by flow cytometer. …”
    Get full text
    Article
  16. 576

    Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China by M. Ch. Semenistaya, Fan Jian-Gao, O. B. Velichenko, Ye. A. Kuznetsova, Ch. S. Pavlov

    Published 2018-08-01
    “…According to the international clinical guidelines, NAFLD screening methods should include elastometry and serological tests to rule out severe liver fibrosis (F> 2). Liver biopsy is carried out at contradictory data of liver elastometry and serological fibrosis markers. …”
    Get full text
    Article
  17. 577

    Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis by Peter Moritz Becher, Frauke Gotzhein, Karin Klingel, Felicitas Escher, Stefan Blankenberg, Dirk Westermann, Diana Lindner

    Published 2017-01-01
    “…Interestingly, cardiac fibrosis declined to basal levels as well. Both cardiac inflammation and fibrosis were reversible, whereas the hemodynamic function remains impaired after healed viral myocarditis in C57BL/6J mice.…”
    Get full text
    Article
  18. 578

    Diagnostic Value of the 13C Methacetin Breath Test in Various Stages of Chronic Liver Disease by Hamizah Razlan, Nurhayaty Muhamad Marzuki, Mei-Ling Sharon Tai, Azhar-Shah Shamsul, Tze-Zen Ong, Sanjiv Mahadeva

    Published 2011-01-01
    “…Area under curve values for fibrosis was 0.62 (0.39–0.86), whilst that for cirrhosis (all stages) was 0.95 (0.91–0.99). …”
    Get full text
    Article
  19. 579

    miR-29c Inhibits Renal Interstitial Fibrotic Proliferative Properties through PI3K-AKT Pathway by Weifeng Feng, Huijun Xie, Jiong Li, Xianxin Yan, Shiping Zhu, Shengyun Sun

    Published 2022-01-01
    “…Renal fibrosis, in particular tubulointerstitial fibrosis, which is characterized by an increased extracellular matrix (ECM) formation and development in the interstitium, is the common end pathway for nearly all progressive kidney disorders. …”
    Get full text
    Article
  20. 580

    Establishment and Mechanism Study of a Primary Ovarian Insufficiency Mouse Model Using Lipopolysaccharide by Si-Ji Lv, Shu-Hui Hou, Lei Gan, Jing Sun

    Published 2021-01-01
    “…Histopathological examination was performed to examine ovarian fibrosis. TUNEL assay was carried out to evaluate granulosa cell apoptosis. …”
    Get full text
    Article